US FDA approves Merck’s drug for kidney cancer


US FDA approves Merck’s drug for kidney cancer

Dec 14 (Reuters) – The U.S. Food and Drug Administration on Thursday approved Merck’s (MRK.N) drug belzutifan for a type of kidney cancer.

The drug, branded as Welireg, is used to treat patients with renal cell carcinoma who have received prior treatment.

Renal cell carcinoma is a disease in which cancer cells are found in the lining of very small tubes in the kidney.

Welireg’s approval is based on data from a late-stage trial, where the drug showed statistically significant and clinically meaningful improvement in progression-free survival (PFS) of patient compared to Novartis’ (NOVN.S) drug, everolimus.

PFS refers to how long a patient lives without the disease getting worse after treatment.

In 2021, the drug was approved for cancers associated with Von Hippel-Lindau Disease, a rare, genetic disorder in which non-cancerous tumors grow in certain parts of the body.

Reporting by Christy Santhosh; Editing by Maju Samuel

Source: Reuters